Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain
Status:
Temporarily Closed
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
NCT#04729959
BN010 , dose level 3 is temporarily closed to accrual, effective August 8, 2023.